Trial Profile
A Randomized Phase II, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Calcineurin inhibitors; Ciclosporin; Tacrolimus
- Indications Liver cancer
- Focus Therapeutic Use
- 03 May 2017 Results (n=42) presented at the 2017 American Transplant Congress.
- 30 May 2016 Status changed from active, no longer recruiting to completed.
- 28 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2016.